RECOVERY & TISSUE REPAIR / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these two recovery-and-repair research peptides.
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective and regenerative peptide. Its effects trace most consistently to angiogenesis — encouraging the growth of new blood vessels into injured tissue by up-regulating the VEGFR2 receptor and activating its downstream Akt-eNOS pathway [4]. It has accelerated healing in rat models of gastric ulcers [5] and appears to modulate brain-gut signaling pathways. Almost all of this is preclinical; as of 2025, human evidence is limited to three small pilot studies [2].
Is BPC-157 a growth hormone?
No. BPC-157 is not growth hormone and does not function as one. It is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice. The connection people sometimes see is that BPC-157 has been reported to sensitize the growth-hormone receptor in tendon fibroblasts — making cells more responsive to the body's own growth hormone rather than replacing it. Sensitizing a receptor is not the same as being the hormone itself. BPC-157 has no growth-hormone-like hormonal activity.
Does BPC-157 work immediately, and how long does it stay in the body?
The peptide clears the bloodstream quickly. The first formal pharmacokinetic study in rats and dogs found an elimination half-life under 30 minutes, with rapid breakdown into small amino-acid fragments [3]. A short half-life means the intact molecule does not linger after dosing. Whether any repair effect follows quickly is a separate question — the published healing data are from animal studies measured over days to weeks, not immediate outcomes — and this site does not advise on timing or regimen [3].
Does BPC-157 damage the liver?
The available data do not indicate liver harm, but the dataset is extremely thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic, cardiac, renal, thyroid or glucose biomarkers, and no adverse events were observed [1]. That is a reassuring early signal from two people in a safety study — not a liver-safety trial. The broader literature stresses that without long-term, large-sample human data, the overall safety profile is genuinely unknown [2].
What is KPV peptide?
KPV is a three-amino-acid peptide — lysine, proline, valine — that corresponds to the C-terminal (tail) sequence, residues 11-13, of the hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It is also written as alpha-MSH(11-13). Its distinguishing property in the research record is that it keeps the parent hormone's anti-inflammatory activity while dropping the skin-darkening (melanogenic) effect that alpha-MSH also produces [10]. KPV is a research chemical with no approved drug or supplement status.
What does KPV peptide do?
In research models, KPV suppresses two major inflammatory signaling pathways — NF-kB and MAP-kinase — reducing the output of pro-inflammatory cytokines such as IL-1beta and TNF-alpha [8]. In the gut it is taken up directly into intestinal epithelial cells via a transporter called PepT1, which is most active in inflamed tissue [8]. The result, in mouse models of colitis, is reduced inflammatory infiltrate, lower myeloperoxidase activity (a marker of inflammation) and faster mucosal recovery [9]. It does not grow blood vessels or build collagen; it quiets the inflammatory signals that can stall healing.
What is KPV peptide used for in research?
KPV is studied chiefly for its potential in gut mucosal inflammation — specifically in mouse models of inflammatory bowel disease such as DSS-induced and TNBS-induced colitis [8][9]. Beyond the gut, a 2006 rabbit study found topical KPV accelerated corneal epithelial wound healing through a nitric-oxide-dependent mechanism [11], and a comprehensive review of alpha-MSH-related tripeptides documents anti-inflammatory and protective effects across skin, eye, airway, joint and organ-injury models [10]. There are no human clinical trials of KPV in any of these contexts [8].
What is KPV peptide good for, according to the research?
The strongest signal in the KPV literature is for calming gut inflammation in preclinical models. KPV reduced colitis severity, shortened recovery time and lowered inflammatory markers in mouse studies [9]. Targeted delivery formulations carrying KPV to inflamed colon tissue outperformed non-targeted versions in mucosal healing [7], and a 2024 combination formulation pairing KPV with an immunosuppressant improved both acute and chronic colitis in mice [6]. A broad review extends anti-inflammatory effects across many tissues [10]. All of this is preclinical; KPV is not an approved treatment for any condition, and no human dose or schedule is discussed on this site.
Are BPC-157 and KPV the same thing?
No — they are mechanistically and structurally distinct. BPC-157 is a fifteen-amino-acid peptide derived from gastric juice protein; its primary studied effect is promoting new blood vessel formation (angiogenesis) [4]. KPV is a three-amino-acid fragment of the hormone alpha-MSH; its primary studied effect is suppressing inflammatory signaling (NF-kB and MAP-kinase pathways) [8]. BPC-157 has a longer preclinical record and three small human pilots; KPV has no human clinical trials at all. They are sometimes discussed together because both turn up in conversations about tissue repair, but they are different molecules working through different mechanisms.
Can either peptide be used in sport?
BPC-157 is explicitly prohibited in sport by the World Anti-Doping Agency at all times under the S0 non-approved-substances category, which covers any pharmacological substance not approved by a regulatory authority [2]. KPV is not listed by name on the current WADA Prohibited List, but as a non-approved peptide its use in any regulated competition context carries risk. A competitive athlete subject to anti-doping rules should treat both compounds with caution and consult the relevant anti-doping authority before any use.
Where can I read the original studies?
The references page lists every source cited across this desk with full author, title, journal and year, along with DOIs and PubMed links wherever available. Every claim on this site is anchored to a numbered citation that appears in that list. Reading the abstracts and methods sections of the primary papers is the most reliable way to understand what was actually studied, in which species, and at what scale.